Search research articles
Contact Us
Filters
Showing results (11-20 of 43) with videos related to
Page
of 5
Sort By:
BJU International
|
February 16, 2011
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer
Shuchi S Pandya, James W Mier, David F McDermott, et al.
The Journal of Biological Chemistry
|
November 10, 2007
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines
David J Panka, Daniel C Cho, Michael B Atkins, et al.
Journal of Cellular and Molecular Medicine
|
February 8, 2013
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells
Shudong Zhu, Matthew B Cohen, Jeffrey D Bjorge, et al.
Gynecologic Oncology Reports
|
October 21, 2020
Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma
Andrey Moiseyenko, Franco Muggia, Thomas Condamine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2013
Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication
Kathleen M Mahoney, Allison Ackerman, Daniel C Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2010
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
Daniel C Cho, Matthew B Cohen, David J Panka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2019
Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
Daniel C Cho, Matthew B Cohen, David J Panka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 10, 2012
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome
Donnette A Dabydeen, Jyothi P Jagannathan, Nikhil Ramaiya, et al.
BJU International
|
March 17, 2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
Toni K Choueiri, Meredith M Regan, Jonathan E Rosenberg, et al.
Investigational New Drugs
|
August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 43) with videos related to
Sort By:
Page
of 5
BJU International
|
February 16, 2011
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer
Shuchi S Pandya, James W Mier, David F McDermott, et al.
The Journal of Biological Chemistry
|
November 10, 2007
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines
David J Panka, Daniel C Cho, Michael B Atkins, et al.
Journal of Cellular and Molecular Medicine
|
February 8, 2013
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells
Shudong Zhu, Matthew B Cohen, Jeffrey D Bjorge, et al.
Gynecologic Oncology Reports
|
October 21, 2020
Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma
Andrey Moiseyenko, Franco Muggia, Thomas Condamine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2013
Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication
Kathleen M Mahoney, Allison Ackerman, Daniel C Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2010
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
Daniel C Cho, Matthew B Cohen, David J Panka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2019
Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
Daniel C Cho, Matthew B Cohen, David J Panka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 10, 2012
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome
Donnette A Dabydeen, Jyothi P Jagannathan, Nikhil Ramaiya, et al.
BJU International
|
March 17, 2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
Toni K Choueiri, Meredith M Regan, Jonathan E Rosenberg, et al.
Investigational New Drugs
|
August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
Page
of 5